Skip to main content
EnnoDC  I  News & Events

News & Events

I  Use the filters to find our latest press releases and upcoming events.

Filter

Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical MedicinePress Releases

Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical Medicine

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategyPress Releases

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy

42nd Annual J.P. Morgan Healthcare ConferenceEvents

42nd Annual J.P. Morgan Healthcare Conference

ICR Consilium Healthcare ConferenceEvents

ICR Consilium Healthcare Conference

BIO Europe Partnering EventEvents

BIO Europe Partnering Event

LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancerPress Releases

LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancer

LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronavirusesPress Releases

LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronaviruses

LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccinePress Releases

LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccine

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal CancerPress Releases

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 MPress Releases

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platformPress Releases

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platformPress Releases

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19Press Releases

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

Filter

Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical MedicinePress Releases

Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical Medicine

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategyPress Releases

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy

LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancerPress Releases

LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancer

LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronavirusesPress Releases

LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronaviruses

LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccinePress Releases

LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccine

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal CancerPress Releases

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 MPress Releases

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platformPress Releases

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platformPress Releases

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19Press Releases

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

EnnoDC  I  France
PariSanté Campus
10, rue d’Oradour-sur-Glane
75015 Paris
France
EnnoDC  I  US
255 Main Street, STE 200
Cambridge, MA 02142-1029
United States
© EnnoDC 2024